BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 14586274)

  • 1. Total tau in cerebrospinal fluid differentiates Alzheimer's disease from vascular dementia.
    Leszek J; Małyszczak K; Janicka B; Kiejna A; Wiak A
    Med Sci Monit; 2003 Nov; 9(11):CR484-8. PubMed ID: 14586274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia.
    Jia JP; Meng R; Sun YX; Sun WJ; Ji XM; Jia LF
    Neurosci Lett; 2005 Jul 22-29; 383(1-2):12-6. PubMed ID: 15936505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnostic value of tau in cerebrospinal fluid in alzheimer disease].
    Hu Y; He S; Wang J
    Zhonghua Yi Xue Za Zhi; 2001 Nov; 81(22):1377-9. PubMed ID: 11930632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
    Hampel H; Buerger K; Zinkowski R; Teipel SJ; Goernitz A; Andreasen N; Sjoegren M; DeBernardis J; Kerkman D; Ishiguro K; Ohno H; Vanmechelen E; Vanderstichele H; McCulloch C; Moller HJ; Davies P; Blennow K
    Arch Gen Psychiatry; 2004 Jan; 61(1):95-102. PubMed ID: 14706948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cerebrospinal fluid protein tau levels in the differential diagnosis of Alzheimer's disease].
    Schonknecht P; Pantel J; Werle E; Hartmann T; Essig M; Baudendistel K; Beyreuther K; Schroder J
    Fortschr Neurol Psychiatr; 2000 Oct; 68(10):439-46. PubMed ID: 11103680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid markers in differential diagnosis of Alzheimer's disease and vascular dementia.
    Boban M; Grbić K; Mladinov M; Hof PR; Süssmair C; Ackl N; Stanić G; Bader B; Danek A; Simić G
    Coll Antropol; 2008 Jan; 32 Suppl 1():31-6. PubMed ID: 18405055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan.
    Nishimura T; Takeda M; Nakamura Y; Yosbida Y; Arai H; Sasaki H; Shouji M; Hirai S; Khise K; Tanaka K; Hamamoto M; Yamamoto H; Matsubayashi T; Urakami K; Adachi Y; Nakashima K; Toji H; Nakamura S; Yoshida H
    Methods Find Exp Clin Pharmacol; 1998 Apr; 20(3):227-35. PubMed ID: 9646285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The measurement of phosphorylated tau in human cerebrospinal fluid as a diagnostic marker for Alzheimer's disease].
    Urakami K; Ito N; Arai H; Ishiguro K; Ohno H; Nakashima K
    Seishin Shinkeigaku Zasshi; 2003; 105(4):393-7. PubMed ID: 12806900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
    Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
    Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated interleukin-6 levels in cerebrospinal fluid of vascular dementia patients.
    Wada-Isoe K; Wakutani Y; Urakami K; Nakashima K
    Acta Neurol Scand; 2004 Aug; 110(2):124-7. PubMed ID: 15242421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
    Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
    Stefani A; Martorana A; Bernardini S; Panella M; Mercati F; Orlacchio A; Pierantozzi M
    J Neurol Sci; 2006 Dec; 251(1-2):124-8. PubMed ID: 17097109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
    Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
    Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease.
    Arai H; Terajima M; Miura M; Higuchi S; Muramatsu T; Machida N; Seiki H; Takase S; Clark CM; Lee VM
    Ann Neurol; 1995 Oct; 38(4):649-52. PubMed ID: 7574462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations.
    Rosso SM; van Herpen E; Pijnenburg YA; Schoonenboom NS; Scheltens P; Heutink P; van Swieten JC
    Arch Neurol; 2003 Sep; 60(9):1209-13. PubMed ID: 12975285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [CSF levels of total tau protein in patients with mild cognitive impairment and Alzheimer's disease].
    Kaiser E; Schönknecht P; Hunt A; Thomann PA; Pantel J; Schröder J
    Z Gerontol Geriatr; 2008 Dec; 41(6):497-501. PubMed ID: 18327693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages.
    Kapaki E; Liappas I; Paraskevas GP; Theotoka I; Rabavilas A
    Int J Geriatr Psychiatry; 2005 Aug; 20(8):722-9. PubMed ID: 16035118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
    Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
    Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease?
    Palumbo B; Siepi D; Sabalich I; Tranfaglia C; Parnetti L
    Funct Neurol; 2008; 23(2):93-6. PubMed ID: 18671910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.